{"date":"2025-01-08","count":3,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6610-2025-01-08-1722-wyfj63","company_id":"6610","company":"安成生技","market":"興櫃","industry":"生技醫療","date":"2025-01-08","time":"17:22:18","subject":"公告本公司用於治療單純型遺傳性表皮分解性水皰症（EBS）之開發中新藥AC-203，獲得西班牙AEMPS同意進行第二/三期人體臨床試驗。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：安成生技（6610），2025-01-08 17:22，「公告本公司用於治療單純型遺傳性表皮分解性水皰症（EBS）之開發中新藥AC-203，獲得西班牙AEMPS同意進行第二/三期」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6612-2025-01-08-1556-1qob46l","company_id":"6612","company":"奈米醫材","market":"上櫃","industry":"生技醫療","date":"2025-01-08","time":"15:56:24","subject":"代子公司 MILLENNIUM BIOMEDICAL INC.公告- 董事長異動公告(母公司改派)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：奈米醫材（6612），2025-01-08 15:56，「代子公司 MILLENNIUM BIOMEDICAL INC.公告- 董事長異動公告(母公司改派)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6612-2025-01-08-1555-st4vqh","company_id":"6612","company":"奈米醫材","market":"上櫃","industry":"生技醫療","date":"2025-01-08","time":"15:55:53","subject":"代子公司 MILLENNIUM BIOMEDICAL INC.公告- 董事成員異動(母公司改派)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：奈米醫材（6612），2025-01-08 15:55，「代子公司 MILLENNIUM BIOMEDICAL INC.公告- 董事成員異動(母公司改派)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}